4.6 Article

The Synergistic Relationship Between Estimated GFR and Microalbuminuria in Predicting Long-term Progression to ESRD or Death in Patients With Diabetes: Results From the Kidney Early Evaluation Program (KEEP)

期刊

AMERICAN JOURNAL OF KIDNEY DISEASES
卷 61, 期 4, 页码 S12-S23

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ajkd.2013.01.005

关键词

Albuminuria; chronic kidney disease; end-stage renal disease; diabetes mellitus; glomerular filtration rate; mortality; nonalbuminuric chronic kidney disease

资金

  1. National Kidney Foundation Inc
  2. Abbott
  3. Amgen
  4. LifeScan
  5. Siemens
  6. Genentech
  7. GM Foundation
  8. Nephroceuticals
  9. Pfizer
  10. National Cancer Institute, National Institutes of Health (NIH) [KM1CA156708]
  11. Clinical and Translational Science Award, National Center for Advancing Translational Sciences (NCATS), NIH [UL1 TR000448, KL2 TR000450, TL1 TR000449]
  12. Department of Veterans Affairs Career Development Award
  13. American Society of Nephrology-Association of Specialty Professors Development Grant in Geriatric Nephrology
  14. American Heart Association
  15. Medtronic Diabetes
  16. Glumetrics
  17. Gilead
  18. NIH [R03AG040638]

向作者/读者索取更多资源

Introduction: Chronic kidney disease may complicate diabetes, often manifesting with reduced glomerular filtration rate (GFR), albuminuria, or both. Although greater albuminuria and lower estimated GFR both predict adverse prognosis, whether a synergistic prognostic interaction occurs in patients with diabetes has not been defined in a large national cohort study. Methods: We used 2000-2011 data from the National Kidney Foundation's Kidney Early Evaluation Program (KEEP) for 42,761 participants with diabetes. Kaplan-Meier survival analysis and multivariable Cox regression were used to ascertain the association of estimated GFR, albumin-creatinine ratio (ACR), and their interaction on all-cause mortality and progression to end-stage renal disease (ESRD) at a median 4 years of follow-up. Results: Of 42,761 participants with diabetes, 8,618 (20.2%) had estimated GFR < 60 mL/min/1.73 m(2), 7,715 (18.0%) had ACR > 30 mg/g, and 2,641 (6.2%) had both. The unadjusted incidence (per 1,000 person-years) of all-cause mortality increased from 3.1 (95% CI, 2.4-3.8) in participants with estimated GFR > 105 mL/min/1.73 m(2) and no albuminuria to 73.7 (95% CI, 54.9-92.5) in participants with estimated GFR < 30 mL/min/1.73 m(2) and macroalbuminuria (P < 0.001). Progression to ESRD likewise increased from 0.2 (95% CI, 0-0.4) to 220.4 (95% CI, 177.2-263.6) per 1,000 person-years (P < 0.001). After adjustment for confounders, both estimated GFR and albuminuria were associated independently with mortality and progression to ESRD, with a strong synergistic interaction (P for interaction < 0.001); estimated GFR < 30 mL/min/1.73 m(2) and macroalbuminuria together were associated with a 5-fold higher risk of mortality and a more than 1,000-fold higher risk of progression to ESRD (compared with patients with estimated GFR > 60 mL/min/1.73 m(2) and ACR < 30 mg/g; P < 0.001 for both outcomes). Conclusions: In this large cohort of diabetic KEEP participants with more than 170,000 person-years of follow-up, both estimated GFR and albuminuria were associated independently with mortality and progression to ESRD, with a strong synergistic interaction. Am J Kidney Dis. 61(4)(S2): S12-S23. (C) 2013 by the National Kidney Foundation, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据